HRMY Stock Risk & Deep Value Analysis
Harmony Biosciences Holdings Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About HRMY Stock
We analyzed Harmony Biosciences Holdings Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran HRMY through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
HRMY Risk Analysis & Red Flags
What Could Go Wrong
Harmony's future growth for 10x potential heavily relies on WAKIX's continued expansion and successful pipeline diversification beyond its current focus. If WAKIX's growth decelerates faster than anticipated or if pipeline efforts fail to yield significant new revenue streams, the company could struggle to expand beyond its current niche, limiting substantial upside.
Risk Matrix
Overall
Moderate
Financial
Medium
Market
Low
Competitive
Medium
Execution
Medium
Regulatory
Low
Red Flags
- ⚠
Q4 2025 EPS significantly missed estimates and declined 55.3% YoY, indicating potential short-term profitability challenges despite revenue growth.
- ⚠
Over-reliance on WAKIX (pitolisant) as its sole marketed product, with no major late-stage pipeline assets visible for transformative growth.
- ⚠
Mixed analyst sentiment, including a recent 'Underperform' rating and price target cut by Bank of America.
Upcoming Risk Events
- 📅
Q1 2026 earnings miss or downward revision of 2026 guidance
- 📅
New competitive treatments for narcolepsy entering the market
- 📅
Adverse regulatory decisions for existing or pipeline products
When to Reconsider
- 🚪
Exit if WAKIX net product revenue guidance for 2026 is significantly lowered or if Q1 2026 earnings show further, sustained margin compression.
- 🚪
Sell if there are significant clinical trial failures for any key pipeline candidates that emerge or if patent challenges arise for WAKIX.
- 🚪
Exit if total cash position (as reported in 10-K/10-Q) shows a sustained and unexpected decline without clear investment justification.
Unlock HRMY Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Harmony Biosciences Holdings Inc (HRMY) Do?
Market Cap
$1.78B
Sector
Healthcare
Industry
Biotechnology
Employees
268
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 1 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome (FXS), rare genetic disorder that causes inherited intellectual disability and autism spectrum disorder; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; and EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies (DEE). The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Visit Harmony Biosciences Holdings Inc WebsiteInvestment Thesis
Harmony Biosciences is an undervalued specialty pharmaceutical company with a strong cash-generating core asset in WAKIX, which continues to show robust revenue growth in a defined niche. Its attractive valuation metrics and recent executive strengthening position it well to leverage its cash reserves for strategic M&A or pipeline development, potentially unlocking significant long-term value and driving growth towards a 10x target, provided new catalysts emerge beyond WAKIX's current trajectory.
Is HRMY Stock Undervalued?
Unlock the full AI analysis for HRMY
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
HRMY Price Targets & Strategy
12-Month Target
$50.00
Bull Case
$65.00
Bear Case
$25.00
Valuation Basis
Based on 15x forward P/E applied to $3.33 est. FY26 EPS = $49.95
Entry Strategy
Consider dollar-cost averaging in the $28-$32 range, particularly if the stock approaches the $28 analyst low target or recent support levels.
Exit Strategy
Take 50% profit around $50-$55, with a stop-loss order placed at $27 to protect against further downside.
Portfolio Allocation
3-5% for moderate risk tolerance
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is HRMY Financially Healthy?
Valuation
P/E Ratio
11.23
PEG Ratio
0.50
Price/Book
2.73
Price/Sales
2.63
Profitability
Gross Margin
77.16%
Operating Margin
24.00%
Net Margin
18.27%
Return on Equity
19.84%
Revenue Growth
21.51%
EPS
$2.71
Balance Sheet
Current Ratio
3.60
Quick Ratio
3.51
Debt/Equity
0.19
Cash & Equivalents
$600.00M
Cash Flow
EBITDA
$218.99M
Other
Beta (Volatility)
0.97
Does HRMY Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable
Moat Sources
2 Identified
The moat is primarily driven by patent protection and regulatory exclusivity for WAKIX, which provides a durable competitive advantage for a defined period. The established brand and physician relationships further strengthen this. However, patent expiry remains a long-term risk.
Moat Erosion Risks
- •Potential for new, more effective therapies for narcolepsy or idiopathic hypersomnia.
- •Erosion of exclusivity or patent challenges for WAKIX.
- •Increased generic competition following patent expiry.
HRMY Competitive Moat Analysis
Sign up to see competitive advantages
HRMY Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral (No specific data available; assume balanced sentiment reflecting current market conditions for a specialty pharma.)
Institutional Sentiment
Mixed. HC Wainwright maintains a 'Buy' with a $55 target, signaling confidence, while Bank of America recently downgraded to 'Underperform' with a $28 target, indicating skepticism.
Insider Activity (Form 4)
Former CFO Sandip Kapadia sold 3,746 shares on January 26, 2026 (a small, likely routine transaction). New CFO Glenn Reicin received a $3,000,000 stock option grant, and COO Peter Anastasiou received 212,241 stock options, indicating new executive alignment with shareholder interests.
Options Flow
Normal options activity (No specific unusual options activity or put/call ratio data identified in the provided research, suggesting typical trading patterns.)
Earnings Intelligence
Next Earnings
2026-05-07
Surprise Probability
Medium
Historical Earnings Pattern
Historical patterns are not explicitly provided in the research; however, the Q4 2025 EPS miss saw a negative market reaction, suggesting sensitivity to earnings quality.
Key Metrics to Watch
Competitive Position
Top Competitor
Jazz Pharmaceuticals (JAZZ)
Market Share Trend
Gaining market share within its specialized narcolepsy and idiopathic hypersomnia niche through WAKIX.
Valuation vs Peers
Harmony Biosciences trades at an attractive trailing P/E of 11.84 and a PEG ratio of 0.43, positioning it below the typical pharmaceutical median P/E (15-18), suggesting it may be undervalued compared to peers given its growth rates.
Competitive Advantages
- •Niche focus and established commercial footprint for rare neurological disorders.
- •Patent protection and regulatory exclusivity for WAKIX.
- •Strong average revenue growth rate (27.3% annually) outperforming the broader pharmaceutical sector.
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive HRMY Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (May 7, 2026)
- •Annual Shareholder Meeting (May 14, 2026)
Medium-Term (6-18 months)
- •Continued WAKIX market penetration in narcolepsy and idiopathic hypersomnia
- •Potential expansion into new indications for pitolisant (WAKIX)
- •Progress on early-stage pipeline assets (if any are announced)
Long-Term (18+ months)
- •Successful acquisition of a late-stage pipeline asset
- •Development of a new blockbuster drug leveraging Harmony's commercial infrastructure
- •Significant expansion into international markets
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for HRMY?
- ✓
Acceleration in WAKIX sales growth and updates on new indication approvals.
- ✓
Announcements of strategic M&A or advancements in a novel, late-stage pipeline asset.
- ✓
Improvements in EPS quality and consistency in subsequent quarters.
Bull Case Analysis
See what could go right with Premium
Competing with HRMY
See how Harmony Biosciences Holdings Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Harmony Biosciences Holdings Inc HRMY | $1.8B | 7.8 | 11.2 | $868.5M | 18.3% | 21.5% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Harmony Biosciences Holdings Inc Makes Money
Harmony Biosciences is a commercial-stage biopharmaceutical company that focuses on developing and commercializing innovative therapies for patients with rare neurological disorders who have unmet medical needs. Its primary and currently sole marketed product is WAKIX (pitolisant), approved for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy, and more recently for EDS in adult patients with idiopathic hypersomnia. The company makes money by manufacturing, marketing, and selling WAKIX to patients via specialized pharmacies and directly to healthcare providers.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Harmony Biosciences Holdings Inc (HRMY)?
As of April 26, 2026, Harmony Biosciences Holdings Inc has a DVR Score of 7.8 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Harmony Biosciences Holdings Inc?
Harmony Biosciences Holdings Inc's market capitalization is approximately $1.8B. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Harmony Biosciences Holdings Inc use?
HRMY is the ticker symbol for Harmony Biosciences Holdings Inc. The company trades on the NGM.
What is the risk level for HRMY stock?
Our analysis rates Harmony Biosciences Holdings Inc's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of HRMY?
Harmony Biosciences Holdings Inc currently has a price-to-earnings (P/E) ratio of 11.2. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Harmony Biosciences Holdings Inc's revenue growing?
Harmony Biosciences Holdings Inc has reported revenue growth of 21.5%. The company is showing strong top-line momentum.
Is HRMY stock profitable?
Harmony Biosciences Holdings Inc has a profit margin of 18.3%. The company is profitable but margins are modest.
How often is the HRMY DVR analysis updated?
Our AI-powered analysis of Harmony Biosciences Holdings Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 26, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for HRMY (Harmony Biosciences Holdings Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.